Deleting adipose FXR exacerbates metabolic defects and induces endocannabinoid lipid, 2-oleoyl glycerol, in obesity
Journal of Lipid Research · 2025
DOI: 10.1016/j.jlr.2025.100754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Weinan Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, IL, USA. Hauptthemen laut MEDLINE: Obesity, Receptors, Cytoplasmic and Nuclear, Endocannabinoids, Glycerides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIDDK NIH HHS, Intramural Research Program, National Institute on Drug Abuse.
Abstract (Originalsprache)
The nutrient sensor farnesoid X receptor (FXR) transcriptionally regulates whole-body lipid and glucose homeostasis. Several studies examined targeting FXR as a modality to treat obesity with varying conflicting results, emphasizing the need to study tissue-specific roles of FXR. We show that deletion of adipocyte Fxr results in increased adipocyte hypertrophy and suppression of several metabolic genes that is akin to some of the changes noted in high-fat diet (HFD)-fed control mice. Moreover, upon HFD challenge, these effects are worsened in adipocyte-specific Fxr knockout mice. We uncover that FXR regulates fatty acid amide hydrolase (Faah) such that its deletion lowers Faah expression. Conversely, FXR activation by its ligand, chenodeoxycholic acid, induces Faah transcription. Notably, HFD results in the reduction of adipose Faah expression in control mice and that Faah inhibition or deletion is linked to obesity. We report that the adipocyte FXR-Faah axis controls local 2-oleoyl glycerol and systemic N-acyl ethanolamine levels. Taken together, these findings show that loss of adipose FXR may contribute to the pathogenesis of obesity and subsequent metabolic defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, IL, USA.
- Department of Materials Science and Engineering, University of Illinois Urbana-Champaign, Urbana, IL, USA.
- Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, USA.
- Department of Kinesiology and Community Health, University of Illinois Urbana-Champaign, Urbana, IL, USA.
- Department of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN, USA.
- Department of Materials Science and Engineering, University of Illinois Urbana-Champaign, Urbana, IL, USA; Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, USA; Cancer Center at Illinoi…
Förderung
- NIDA NIH HHS
- NIDDK NIH HHS
- Intramural Research Program, National Institute on Drug Abuse
- National Institute of Diabetes and Digestive and Kidney Diseases
- Cancer Center at Illinois
- Office of Naval Research Global
Zitieren
APA
Zhou, W., Bandara, S. R., Ko, K., Akinrotimi, O., Hernández-Saavedra, D., Richter, E., Brauer, N., Woodward, T. J., Bradshaw, H. B., Leal, C., & Anakk, S. (2025). Deleting adipose FXR exacerbates metabolic defects and induces endocannabinoid lipid, 2-oleoyl glycerol, in obesity. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100754
Vancouver
Zhou W, Bandara SR, Ko K, Akinrotimi O, Hernández-Saavedra D, Richter E, et al. Deleting adipose FXR exacerbates metabolic defects and induces endocannabinoid lipid, 2-oleoyl glycerol, in obesity. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100754
BibTeX
@article{Zhou2025,
author = {Zhou, Weinan and Bandara, Sarith R and Ko, Kyungwon and Akinrotimi, Oludemilade and Hernández-Saavedra, Diego and Richter, Emily and Brauer, Noah and Woodward, Taylor J and Bradshaw, Heather B and Leal, Cecilia and Anakk, Sayeepriyadarshini},
title = {Deleting adipose FXR exacerbates metabolic defects and induces endocannabinoid lipid, 2-oleoyl glycerol, in obesity},
journal = {Journal of Lipid Research},
year = {2025},
doi = {10.1016/j.jlr.2025.100754}
}
EUVIMED